Factors predicting survival after transarterial chemoembolization of unresectable hepatocellular carcinoma

Results: Included in this study were 71 patients of whom there were 57 (80.3 %) males, with a mean age of 51.9±12.1 years (range: 18-76 years). The mean follow-up period was 12.5±10.7 months. A total of 31 (43.7%) patients had only one session of transarterial chemoembolization, 17 (23.9%) underwent 2 and 11 (15.5%) had 3 or more sessions. On univariate analysis, significant factors that predicted survival included serum bilirubin (P=0.02), esophageal varices (P=0.002), Cancer of the Liver Italian Program score (P=0.003), tumor size (P=0.005), >3 sessions of transarterial chemoembolization (P=0.006) and patient's age (P=0.001). Cox regression analysis showed that tumor size of <5cm (P=0.025), absence of varices (P=0.035), Cancer of the Liver Italian Program class (P=0.015), and >1 transarterial chemoembolization session (P=0.004) were associated with better survival.

Background: Transarterial chemoembolization is the preferred treatment for unresectable, intermediate-stage hepatocellular carcinoma. Survival after transarterial chemoembolization can be highly variable. The purpose of this study is to identify the factors that predict overall survival of patients with unresectable hepatocellular carcinoma who undergo transarterial chemoembolization as the initial therapy.

Methods: We included patients who underwent transarterial chemoembolization from 2007 to 2012 in this study. Patient’s age, gender, cause of cirrhosis, Child-Turcotte-Pugh score, model of end-stage liver disease score, Cancer of the Liver Italian Program score, Okuda stage, alpha-fetoprotein level, site, size and number of tumors were recorded. Radiological response to transarterial chemoembolization was assessed by computerized tomography scan at 1 and 3 months after the procedure. Repeat sessions of transarterial chemoembolization were performed according to the response. We performed survival assessment and all patients were assessed for survival at the last follow-up.

Conclusion: Our study demonstrates that survival after transarterial chemoembolization is predicted by tumor size, Cancer of the Liver Italian Program classification, bilirubin <2.0 mg/dl, absence of varices and >3 transarterial chemoembolization sessions.